BLOCKStrain Technology Corp. (TSX:V: DNAX.V) (OTC: BKKSF) (“BLOCKStrain”), creator of the first Blockchain-secured, fully-integrated IP tracking platform for the cannabis industry, today announced it has appointed Dr. James LaValle as it Chief Medical Manager. In this new role, Dr. LaValle will provide leadership and direction with respect to scientific and medical aspects of the core software of the company, as well as areas of additional product and business development.
Dr. James LaValle has more than 40 years of experience in the natural products industry as a clinician, industry consultant and educator. He has dedicated his professional career to becoming a voice for the emerging value of the natural product industry, with particular emphasis on the need for quality standards and transparency of ingredients in order to ensure consumer safety and efficacy.
“While Cannabidiol from hemp and cannabis products are taking the consumer and medical markets by storm, to date, this market segment has been fraught with quality and contamination issues that have tarnished the enormous value that these compounds can provide consumers. The BLOCKStrain technology represents a necessary evolution in ensuring product quality by tracking and reporting CBD and Cannabis ingredients starting from the soil all the way to the products on the store shelf”, stated Dr. LaValle. “The CBD/Cannabis industry must deliver quality finished goods to a level that inspires consumer confidence and provides them with safe products. Verification of the level and type of active ingredients as well as absence of impurities should be simple, but the industry is riddled with inconsistent and in some cases dangerous final products. I firmly believe BLOCKStrain has the potential to become a new standard for testing and reporting purity and content safety of not just cannabis, but other natural products as well.”
“Dr. LaValle’s immense expertise in the nutraceutical industry, and his dedication to ensuring high quality product standards is directly in line with BLOCKStrain’s mission of bringing transparency and integrity to the cannabis industry. With our technology, licensed producers, craft growers, other industry participants and most importantly patients and customers, can take affirmative action to ensure their products are as advertised.” said Robert Galarza, CEO of BLOCKStrain. “Dr. LaValle’s valued insight and well-established brand presence in the nutraceutical industry is unquestioned, and we are excited to have him as a key part of our growth strategy in cannabis and beyond.”
Dr. LaValle is the recipient of many prestigious awards. He was one of nine Americans chosen for the Inaugural Dietary Supplement Information Bureau Board, and was also awarded the Clinician of the Year Award from the Natural Products Association. He has authored 4 databases on natural products and teaches application of natural compounds in clinical practice to health care professionals around the world. In addition, he has 35 years of clinical practice in integrative medicine.
In connection with this appointment BLOCKStrain has agreed to grant Dr. LaValle stock options to acquire up to 250,000 common shares in the capital of BLOCKStrain, subject to the terms of a stock option agreement to be entered into by the parties.
SOURCE BLOCKStrain Technology Corp.
